Veralox Therapeutics
Signal active
Organization
Contact Information
Overview
Veralox Therapeutics develops small molecule therapeutics that treat the underlying pathologies of thrombosis and type one diabetes. Based on an understanding of the molecular mechanisms of these diseases, these efforts will lead to new treatment paradigms and better outcomes for patients.
About
Industries
Biotechnology, Pharmaceutical, Medical, Therapeutics
Founded
2017
Employees
1-10
Headquarters locations
United States, North America
Social
N/A
Profile Resume
Veralox Therapeutics headquartered in United States, North America, operates in the Biotechnology, Pharmaceutical, Medical, Therapeutics sector. The company focuses on Biotechnology and has secured $3.0B in funding across 64 round(s). With a team of 1-10 employees, Veralox Therapeutics is actively contributing to advancements in Biotechnology. Their latest funding round, Debt Financing - Veralox Therapeutics, raised $1.5M. Discover more about their projects, partnerships, and impact on our platform.
Funding Rounds
Funding rounds
4
Investors
0
Lead Investors
0
Total Funding Amount
$47.5M
Details
2
Veralox Therapeutics has raised a total of $47.5M in funding over 2 rounds.
| Announcement date | Transaction name | Number of Investors | Money raised | Lead Investor |
|---|---|---|---|---|
| 2019 | Seed | 5.4M | ||
| 2021 | Early Stage Venture | 16.6M |
Investors
Veralox Therapeutics is funded by 37 investors.
| Investor Name | Lead Investor | Funding Round | Partners |
|---|---|---|---|
| JDRF T1D Fund | - | FUNDING ROUND - JDRF T1D Fund | 24.0M |
| Ben Scruggs | - | FUNDING ROUND - Ben Scruggs | 24.0M |
| Veralox Therapeutics | - | FUNDING ROUND - Veralox Therapeutics | 24.0M |
| Hatteras Venture Partners | - | FUNDING ROUND - Hatteras Venture Partners | 24.0M |
Recent Activity
There is no recent news or activity for this profile.